



Retraction Note: Inhibition of hTERT Gene Expression by Silibinin-Loaded PLGA-PEG-Fe₃O₄ in T47D Breast Cancer Cell Line

Zohreh Ebrahimnezhad^{1,2}, Nosratollah Zarghami^{1,2*}, Manoutchehr Keyhani³, Soumaye Amirsaadat¹, Abolfazl Akbarzadeh⁴, Mohammad Rahmati², Zohreh Mohammad Taheri⁵, Kazem Nejati-Koshki⁶

¹ Tuberculosis and Lung Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

² Department of Clinical Biochemistry and Laboratory, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

³ Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran

⁴ Faculty of Advanced Medical Sciences, Department of Medical Nanotechnology, Tabriz University of Medical Sciences, Tabriz, Iran

⁵ National Research Institute of Tuberculosis and Lung Diseases, Tehran, Iran

⁶ Faculty of Advanced Medical Sciences, Department of Medical Biotechnology, Tabriz University of Medical Sciences, Tabriz, Iran

Article Info



Article Type:

Retraction Note

Article History:

ePublished: 16 Sep. 2018

This paper was published in *BioImpacts* in 2013 (doi: 10.5681/bi.2013.005).¹ Based on an email received from a researcher recently, we were informed that this published paper presented some data (i.e., Fig. 3a and 3b) as same as data presented in three other published papers (i.e., doi: 10.1111/Cbdd.12318; doi: 10.2147/Ijrn.s24326; and doi: 10.1186/1477-3155-10-46),²⁻⁴ which are considered as the ethical misconduct.

This issue was brought up with and comprehensively investigated by the editorial team of *BioImpacts* through comparison of the papers and the within-data.

As a result, in accordance with the Committee on Publication Ethics (COPE), the editors decided to retract this paper. The authors were informed and advised on this serious ethical breach.

Based on the COPE guidelines on the retraction, *BioImpacts* considers retracting a publication if:

- It has clear evidence that the findings are unreliable, either as a result of misconduct (e.g., data fabrication and/or falsification) or honest error (e.g. miscalculation or experimental error).
- The findings have previously been published elsewhere without proper crossreferencing, permission or justification (i.e. cases of redundant publication).

As a peer-review multidisciplinary international "Publish Free" and "Access Free" journal, *BioImpacts* strongly adheres to the "Publication Ethics", and its foremost goal is to preserve the integrity of the scientific reports in the highest standards, therefore, the journal takes all issues of publication misconduct seriously.

References

1. Ebrahimnezhad Z, Zarghami N, Keyhani M, Amirsaadat S, Akbarzadeh A, Rahmati M, et al. Inhibition of htert gene expression by silibinin-loaded PLGA-PEG-Fe₃O₄ In T47d breast cancer cell line. *Bioimpacts* 2013; 3(2): 67-74. doi: 10.5681/Bi.2013.005
2. Hosseinasab S, Pashaei-Asl R, Khandaghi Aa, Nasrabadi Ht, Nejati-Koshki K, Akbarzadeh A, et al. Synthesis, characterization, and in vitro studies of PLGA-PEG nanoparticles for oral insulin delivery. *Chem Biol Drug Des* 2014; 84: 307-15. doi:10.1111/Cbdd.12318
3. Akbarzadeh A, Mikaeili H, Zarghami N, Mohammad R, Barkhordari A, Davaran S. Preparation and in vitro evaluation of doxorubicin-loaded Fe₃O₄ magnetic nanoparticles modified with biocompatible copolymers. *Int J Nanomedicine* 2012; 7: 511-26. doi:10.2147/Ijrn.s24326
4. Akbarzadeh A, Samiei M, Joo Sw, Anzaby M, Hanifehpour Y, Nasrabadi Ht, *Et Al*. Synthesis, characterization and in vitro studies of doxorubicin-loaded magnetic nanoparticles grafted to smart copolymers on A549 lung cancer cell line. *J Nanobiotechnology* 2012; 10: 46. doi:10.1186/1477-3155-10-46



*Corresponding author: Nosratollah Zarghami, Email: zarghami@tbzmed.ac.ir



© 2018 The Author(s). This work is published by BioImpacts as an open access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by-nc/4.0/>). Non-commercial uses of the work are permitted, provided the original work is properly cited.